Sensor-driven climate
Temperature, humidity, CO₂ and nutrient solution are measured and regulated continuously.
The project
Studio Verde in detail.
Vision, process, facility, growth plan, technology, offtake and investment: everything about the project on one page.
01 · Why Studio Verde
Medical cannabis Europe can rely on.
Patients and pharmacies need the same quality every time. Much of today's supply varies from batch to batch, is hard to trace or travels thousands of kilometres. We grow in Switzerland, to pharmaceutical standards, with every batch documented from clone to delivery.
We know the process
- Facility planned room by room, with GACP and GMP separated
- SOPs, quality system and traceability with Cannavigia
- Licensing path with Swissmedic, supported by Kellerhals Carrard
- Cultivation led by a founder who has grown since the early days of the Swiss CBD market
GACP, built for GMP
Separate zones, gowning locks, documented SOPs and a quality system from day one.
Own genetics
Mother plants in-house, fixed 62-day cycles, identical conditions in every run.
Batch by batch
Every plant is digitally tracked from clone to hand-over.
02 · From clone to patient
One flow, two standards.
03 · The facility
Every room has a purpose.
Explore the floor plan in 3D. Switch between the three build phases, show the supply and exhaust air system and tap any room for details.
Supply airExhaust airGMP
Model based on the current floor plan (April 2026); dimensions are approximate.
04 · Growth plan
Start lean. Scale on proven ground.
Harvest rhythm
Rooms start 14 days apart, so harvests arrive in a steady rhythm. At full build: one harvest about every 17 days.
Business plan · Phase 1
Not public
Revenue, costs and operating result 2027–2030
Shared with investors in the presentation, together with the cash-flow plan.
Request the presentationAssumptions
- Plants per m²
- 6
- Yield per plant
- 85 → 100 g
- Cycles per room / year
- 4 → 5
- Price per kg
- CHF 1'800 → 2'500
- CAPEX Phase 1
- CHF 449'400
- CAPEX Phase 2 / 3
- In the presentation
Source: business plan, October 2026 (2 flower rooms plus research room). Planning figures, not guaranteed.
05 · Technology
A grow room that reports itself.
From Phase 2, flower room 3 runs as our experimental room: new technology is tested there under live monitoring before it reaches production. Sensors, cameras and automation rules keep every room on its recipe and every batch documented.
01SenseClimate, root zone, light, camera
02AnalyseCompare against the recipe for this day
03ActAdjust air, water, light automatically
04DocumentEvery value logged to the batch record
Concept interface with simulated data. Planned sensor stack: Growlink controllers, climate and root-zone sensors, canopy cameras, Cannavigia batch records.
06 · Offtake
~245 kg
Dried flower · Phase 1 · production year 2027
Secure your allocation of our first harvests.
Rising to 306–360 kg a year from 2028 and 612–720 kg once all four flower rooms run.
- Standard
- GACP, built for GMP
- Harvests 2027
- 8, from May
- Per harvest
- ~30 kg
- Profile
- Terpene-rich · THC 20–26 %
- Traceability
- Batch by batch
What you can take
~30 kg per harvest, 8 harvests in 2027, around 20 a year once all four rooms run.
Reserve a share of every harvest or a full annual volume under one offtake agreement.
Every batch traceable from clone to hand-over, recorded in Cannavigia.
Dried, processed and packaged in our own GMP zone, bulk or patient-ready.
Who we are looking for
Licensed partners who can take whole harvests, in Switzerland and in European medical markets.
- Pharmaceutical manufacturers & processorsLicensed to process cannabis for medical use (HMG and BetmG).
- Medical cannabis distributors & wholesalersSupplying pharmacies and hospitals in Switzerland.
- EU importersFor example Germany; export with an individual Swissmedic permit per shipment.
- Extract & formulation producersBulk flower as raw material for extracts and finished medicines.
RequirementA Swissmedic licence to handle controlled substances (BetmG), or the import licence of the receiving country.
- 01Letter of intentNon-binding, volumes and timing
- 02SpecificationQuality profile and documentation
- 03Offtake agreementEntire harvest per cultivation permit
- 04DeliveryPer harvest, with batch records
Planned output, not guaranteed. Offtake starts with a non-binding letter of intent. Swissmedic requires a written offtake agreement for the entire harvest of each cultivation permit, with a buyer licensed to handle controlled substances (BetmG).
Funding round open
07 · Invest
Invest in a new standard.
A licensed, capital-efficient entry into Europe's regulated medical cannabis market, built in Switzerland in three clear phases.
~245 kgfirst-year output 2027
Not publicRevenue 2027 · in the presentation
Not publicOperating result · in the presentation
×2canopy in Phase 2, same building
271'368
medical cannabis patients in Germany alone (2024), Europe's largest market.
Cannabis in Europe, Feb 2025CHF 2.80–3.80
per gram: Swiss import prices for EU-GMP flower above 20 % THC. GACP flower: CHF 1.60–1.90.
GCX Global Cannabis Report, Spring 20253 phases
Existing building, modular expansion: capital follows proven output.
Business plan, Oct 2026- 2026Funding & incorporation
- 2026Build-out & GACP licensing
- 03/2027First cycle
- 05/2027First harvest
- 2028Phase 2: rooms 3–4
- TBDPhase 3: GMP zone
Figures are planning estimates from the business plan (Oct 2026), before depreciation and tax. This is not an offer of securities.
08 · Contact
Let's talk.
Tell us who you are and what you are looking for.
We reply within two working days.
Or write directly: contact@studioverde.ch